Clinical Trial Update: A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating intravitreal KSI-101 for macular edema secondary to inflammation is currently recruiting. The study is sponsored by Kodiak Sciences I…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Edema Secondary to Inflammation

Drugs mentioned

• KSI-101

Snippet

Sponsor: Kodiak Sciences Inc | Conditions: Macular Edema Secondary to Inflammation | Phase 3 | Status: RECRUITING